Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Fate Therapeutics
(NQ:
FATE
)
4.080
+0.180 (+4.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Fate Therapeutics
< Previous
1
2
3
4
5
6
7
8
9
Next >
FATE Stock Earnings: Fate Therapeutics Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
FATE stock results show that Fate Therapeutics beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
May 09, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Forecasting The Future: 8 Analyst Projections For Fate Therapeutics
May 06, 2024
Via
Benzinga
Fate Therapeutics to Webcast Conference Call Reporting First Quarter 2024 Financial Results and Operational Updates
May 06, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Where Fate Therapeutics Stands With Analysts
April 11, 2024
Via
Benzinga
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
May 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting
April 22, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
April 10, 2024
Via
Benzinga
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference
April 03, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Evaluating Fate Therapeutics: Insights From 5 Financial Analysts
March 19, 2024
Via
Benzinga
Cracking The Code: Understanding Analyst Reviews For Fate Therapeutics
February 27, 2024
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
April 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement
March 19, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
March 05, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Recap: Fate Therapeutics Q4 Earnings
February 26, 2024
Via
Benzinga
Fate Therapeutics to Present at Upcoming March Investor Conferences
March 01, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Domino's To Rally More Than 15%? Here Are 10 Top Analyst Forecasts For Tuesday
February 27, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
February 26, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for Fate Therapeutics
November 09, 2023
Via
Benzinga
Earnings Scheduled For February 26, 2024
February 26, 2024
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is projected to report quarterly earnings at $0.23 per share on revenue of $477.73 million.
Via
Benzinga
A Preview Of Fate Therapeutics's Earnings
February 23, 2024
Via
Benzinga
Recap: Fate Therapeutics Q3 Earnings
November 08, 2023
Via
Benzinga
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
February 02, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Billionaire Steve Cohen Is Betting Big on Fate Therapeutics (FATE) Stock
January 29, 2024
Billionaire Steve Cohen is taking a massive stake in this little-known biotech company, leading FATE stock to surge more than 17%.
Via
InvestorPlace
Fate Therapeutics Announces Initiation of Phase 1 Clinical Trial for FT825 / ONO-8250 in Patients with HER2-expressing Advanced Solid Tumors
January 08, 2024
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
Pinstripes, SoFi Technologies And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
January 03, 2024
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 60 points on Wednesday. Shares of Pinstripes (NYSE: PNST) shares fell in pre-market trading after surging 22% on...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Fate Therapeutics Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 13, 2023
From
Fate Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 12, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.